Munger Mode rating: 2 out of 5 — Sell. Our own rating from the research report below, on business quality first: moat durability and management, with price separating the top three.
Reference price: about $179 per share. This is the October 30 post-earnings trading range of $175 to $181. I could not find a live quote for today. Market capitalization is about $11.3B on roughly 62.9M shares. DaVita is a good business with a bad balance sheet, and the price does not pay us for the difference. Business: A scale operator in outpatient dialysis, a service patients cannot skip. Two firms, DaVita and Fresenius, hold most of the U.S. market. Entry is hard, but the main prices are set by Medicare or negotiated with a handful of insurers. Valuation: Management guides to adjusted EPS of $14.30 to $15.20. At $179 that is about 12x earnings and about 10.5x EV to adjusted operating income. That looks cheap. It is cheap for reasons, and our own estimate of intrinsic value ($150 to $200 per share, $180 at the center) is roughly where the stock trades.
Recent filings analysed: 10-Q (2026-10-29), 8-K (2026-10-29), 10-Q (2026-08-04), 8-K (2026-08-04).
Stock screener · Superinvestor 13F holdings · Analyst sentiment